Wearable lab on a chip could ID bacteria, cancer

Wearables could one day soon analyze sweat for certain proteins to detect breast and lung cancer. A study, published in Lab on a Chip, described the development of biosensor technology for wearable devices to monitor health and identify bacteria and viruses.

Engineers from Rutgers University invented the lab on a chip with electronically barcoding microparticles, giving diseases unique barcodes. The technology can identify bacteria, viruses and other pollutants. The device is being adapted to additionally scan for biomarkers like the prostate-specific antigen.

"This is really important in the context of personalized medicine or personalized health monitoring," said Mehdi Javanmard, an assistant professor in the department of electrical and computer engineering at Rutgers University-New Brunswick. "Our technology enables true labs on chips. We're talking about platforms the size of a USB flash drive or something that can be integrated onto an Apple Watch, for example, or a Fitbit."

With the electronic detection of microparticles, researchers are able to fit the complex testing system within a wearable device. In testing, researchers reported the sensors to be more than 95 percent accurate in identifying biomarkers.

"Imagine a small tool that could analyze a swab sample of what's on the doorknob of a bathroom or front door and detect influenza or a wide array of other virus particles," said Javanmard. "Imagine ordering a salad at a restaurant and testing it for E. coli or Salmonella bacteria. That kind of tool could be commercially available within about two years, and health monitoring and diagnostic tools could be available within about five years.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup